DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04923269

CompletedPhase 1

A Study of LY3532226 in Healthy Participants

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3532226 in Healthy Participants

Asset

Macupatide

Subcutaneous · GIP agonist

Listed sites

1

Recruiting sites

—

Enrollment

41

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-40•Healthy volunteers

Primary endpoint

•Serious AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04923269
Org study ID17834
Secondary IDJ2V-MC-GZLAEli Lilly and Company

Timeline

Milestones

Study start2021-06-10actual
Study first posted2021-06-11actual
Primary completion2021-10-28actual
Study completion2021-10-28actual
Last update posted2021-12-17actual

Assets

Investigational agents

Macupatide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Overtly healthy males or females not of childbearing potential.
•Body mass index (BMI) within the range of 18.5 to 40 kilograms per meter squared (kg/m²), inclusive

Exclusion criteria

•Have a significant history of or current CV (e.g., myocardial infarction, congestive heart failure, cerebrovascular accident, venous thromboembolism), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk while taking the study intervention; or of interfering with the interpretation of data
•Have a history of malignancy within 5 years prior to screening
•Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis
•Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2X the upper limit of normal (ULN) or total bilirubin level (TBL) >1.5X ULN
•Have serum triglyceride level ≥5 mmol/L (442.5 mg/dL)
•Have undergone any form of bariatric surgery
•Have received systemic or inhaled glucocorticoid therapy (excluding topical, intraarticular, and intraocular preparations); for more than 14 consecutive days within 4 weeks before screening

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline up to Week 8

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226

Time frame:Day 1 through Day 43

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226

Time frame:Day 1 through Day 43

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Time to Maximum Concentration (Tmax) of LY3532226

Time frame:Day 1 through Day 43

Tmax

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.